{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:45:00Z","timestamp":1787312700237,"version":"build-2736575974"},"reference-count":24,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1136\/ejhpharm-2021-002937","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T13:21:04Z","timestamp":1638537664000},"page":"64-69","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Widening the net: a literature review of antimicrobial agents with potential suitability for outpatient parenteral antimicrobial therapy services\u2014the importance of storage and stability"],"prefix":"10.1136","volume":"30","author":[{"given":"Abi","family":"Jenkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Shanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Santillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"2024112020250968000_30.2.64.1","unstructured":"Carter PR . Transforming NHS aseptic services in England. a national report for the Department of health and social care. Available: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/931195\/aseptic-pharmacy.pdf"},{"key":"2024112020250968000_30.2.64.2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-002729"},{"key":"2024112020250968000_30.2.64.3","doi-asserted-by":"crossref","DOI":"10.1136\/archdischild-2016-311535.32","article-title":"What is the maximum temperature reached in elastomeric devices under simulated OPAT conditions?","volume":"101","author":"Merwe","year":"2016","journal-title":"Arch Dis Child"},{"key":"2024112020250968000_30.2.64.4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.medmal.2020.10.019","article-title":"Home intravenous antibiotherapy and the proper use of elastomeric pumps: systematic review of the literature and proposals for improved use","volume":"51","author":"Diamantis","year":"2021","journal-title":"Infect Dis Now"},{"key":"2024112020250968000_30.2.64.5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw582"},{"key":"2024112020250968000_30.2.64.6","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2019-001875"},{"key":"2024112020250968000_30.2.64.7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/DDDT.S230459","article-title":"Suitability of amoxicillin-clavulanic acid for administration via prolonged infusion","volume":"14","author":"Fawaz","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"2024112020250968000_30.2.64.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2018.04.003"},{"key":"2024112020250968000_30.2.64.9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijid.2020.11.176","article-title":"Stability of antimicrobial agents in an elastomeric infusion pump used for outpatient parenteral antimicrobial therapy","volume":"103","author":"Akahane","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2024112020250968000_30.2.64.10","first-page":"91","article-title":"Cefazolin and piperacillin\/tazobactam stability related to environmental factors in drug infusion bag: first step required before therapeutic drug monitoring","volume":"32","author":"Metsu","year":"2018","journal-title":"Fundamental and Clinical Pharmacology"},{"key":"2024112020250968000_30.2.64.11","first-page":"50","article-title":"Stability study of cefepime in NaCl at different storage times and temperatures","volume":"33","author":"Ressault","year":"2019","journal-title":"Fundamental and Clinical Pharmacology"},{"key":"2024112020250968000_30.2.64.12","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2017-001221"},{"key":"2024112020250968000_30.2.64.13","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2019-002093"},{"key":"2024112020250968000_30.2.64.14","doi-asserted-by":"publisher","DOI":"10.1177\/0018578718779009"},{"key":"2024112020250968000_30.2.64.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.10.006","article-title":"Comparative in vitro antimicrobial potency, stability, colouration and dissolution time of generics versus innovator of meropenem in Europe","volume":"55","author":"Delattre","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2024112020250968000_30.2.64.16","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2018-001699"},{"key":"2024112020250968000_30.2.64.17","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2016-001170"},{"key":"2024112020250968000_30.2.64.18","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2018-001515"},{"key":"2024112020250968000_30.2.64.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236198"},{"key":"2024112020250968000_30.2.64.20","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002340"},{"key":"2024112020250968000_30.2.64.21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/jppr.1746","article-title":"Stability of buffered benzylpenicillin and flucloxacillin for a paediatric outpatient parenteral antibiotic therapy service","volume":"51","author":"Smith","year":"2021","journal-title":"J Pharm Pract Res"},{"key":"2024112020250968000_30.2.64.22","unstructured":"Jamieson Drummond C C , Ozolina L . Assessing the stability of ceftolozane\/tazobactam (ZERBAXA\u00ae) at 5 mg\/mL and 20 mg\/mL following reconstitution and dilution in 0.9% saline in two commercially available elastomeric devices. Available: https:\/\/e-opat.com\/wp-content\/uploads\/2020\/01\/OPAT2019-ZerbaxaPoster-28Nov.pdf"},{"key":"2024112020250968000_30.2.64.23","unstructured":"NHS Pharmaceutical Quality Assurance Committee . A standard protocol for deriving and assessment of stability- Part 1 aseptic Preparations- small molecules, 2020. Available: https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2020\/08\/Stability-Part-2-Biopharmaceuticals-v4-Aug-2020.pdf"},{"key":"2024112020250968000_30.2.64.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221391","article-title":"Overcoming stability challenges during continuous intravenous administration of high-dose amoxicillin using portable elastomeric pumps","volume":"14","author":"Binson","year":"2019","journal-title":"PLoS One"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2021-002937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T23:25:56Z","timestamp":1732145156000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2021-002937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,21]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/ejhpharm-2021-002937"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2021-002937","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]}}}